Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: Effect of age and left ventricular systolic function

Journal of Cardiovascular Magnetic Resonance

Volumn 15, Issue 1, 2013, Pages

  Hor, Kan N ^a   Taylor, Michael D ^b   Al Khalidi, Hussein R ^c   Cripe, Linda H ^a   Raman, Subha V ^d   Jefferies, John L ^b   O'Donnell, Robert ^e   Benson, D Woodrow ^f   Mazur, Wojciech ^g  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF CINCINNATI   (United States)

^f Children's Hospital of Wisconsin ^*  (United States)

^g CHRIST HOSPITAL   (United States)

Author keywords

Cardiovascular magnetic resonance; Duchenne muscular dystrophy; Ejection fraction; Late gadolinium enhancement; Myocardial fibrosis

Indexed keywords

GADOLINIUM;

ADOLESCENT; ADULT; AGE; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CHILD; CONTRAST ENHANCEMENT; DRUG DISTRIBUTION; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART RATE; HUMAN; LATE GADOLINIUM ENHANCEMENT; LEFT VENTRICULAR SYSTOLIC FUNCTION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CONTRAST MEDIA; DISEASE PROGRESSION; GADOLINIUM; HEART DISEASES; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MUSCULAR DYSTROPHY, DUCHENNE; MYOCARDIUM; OHIO; PREDICTIVE VALUE OF TESTS; PREVALENCE; RETROSPECTIVE STUDIES; STROKE VOLUME; SYSTOLE; TERTIARY CARE CENTERS; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 84890472845     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-15-107     Document Type: Article

References (47)

1. Update on the treatment of Duchenne muscular dystrophy. Rodino-Klapac LR, Mendell JR, Sahenk Z, Curr. Neurol. Neurosci. Rep. 2013 13 3 332 23328943
2. Online Mendelian Inheritance in Man, OMIM® Baltimore, MD: Johns Hopkins University MIM Number: {300377}: {11/28/12}: World Wide Web URL: http://www.omim.org/
3. Population frequencies of inherited neuromuscular diseases-a world survey. Emery AE, Neuromuscul. Disord. 1991 1 1 19 29 10.1016/0960-8966(91) 90039-U 1822774
4. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Hoffman EP, Brown RH Jr, Kunkel LM, Cell 1987 51 6 919 28 10.1016/0092-8674(87) 90579-4 3319190
5. Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy. Fischmann A, et al. J. Neurol. 2012 260 4 969 74 23138982
6. Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the motor function measure. Vuillerot C, et al. Dev. Med. Child Neurol. 2010 52 1 60 5 10.1111/j.1469-8749.2009.03316.x 19453691
7. Report on the 124th ENMC International workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands. Bushby K, et al. Neuromuscul. Disord. 2004 14 8-9 526 34 15336694 (Pubitemid 39141708)
8. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilaton. Eagle M, et al. Neuromuscul. Disord. 2002 12 926 9 10.1016/S0960-8966(02)00140-2 12467747 (Pubitemid 35408673)
9. Transition to adulthood for young men with Duchenne muscular dystrophy: research from the UK. Abbott D, Carpenter J, Bushby K, Neuromuscul. Disord. 2012 22 5 445 6 10.1016/j.nmd.2012.02.004 22425491
10. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Bushby K, et al. Lancet Neurol. 2010 9 2 177 89 10.1016/S1474-4422(09)70272-8 19945914
11. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Bushby K, et al. Lancet Neurol. 2010 9 1 77 93 10.1016/S1474-4422(09)70271-6 19945913
12. The heart in muscular dystrophy. Markham LW, Spicer RL, Cripe LH, Pediatr. Ann. 2005 34 7 531 5 16092627 (Pubitemid 41073053)
13. All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. Schram G, et al. J. Am. Coll. Cardiol. 2013 61 9 948 54 10.1016/j.jacc.2012.12.008 23352781
14. Patterns of left ventricular remodeling in patients with Duchenne muscular dystrophy: a cardiac MRI study of ventricular geometry, global function, and strain. Mazur W, et al. Int. J. Cardiovasc. Imaging 2012 28 1 99 107 10.1007/s10554-010-9781-2 21222036
15. Autopsy analyses of the muscular dystrophies. Moriuchi T, et al. Tokushima J. Exp. Med. 1993 40 1-2 83 93 8211986
16. Alterations in regional myocardial metabolism, perfusion, and wall motion in Duchenne muscular dystrophy studied by radionuclide imaging. Perloff JK, Henze E, Schelbert HR, Circulation 1984 69 1 33 42 10.1161/01.CIR.69.1.33 6605817 (Pubitemid 14215859)
17. The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis. Frankel K, Rosser R, Hum. Pathol. 1976 7 375 86 10.1016/S0046-8177(76)80053-6 939536
18. Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy. Silva MC, et al. J. Am. Coll. Cardiol. 2007 49 18 1874 9 10.1016/j.jacc.2006.10.078 17481447 (Pubitemid 46661108)
19. Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy? Puchalski MD, et al. Int. J. Cardiovasc. Imaging 2009 25 1 57 63 10.1007/s10554-008-9352-y 18686011
20. Comparison between manual and semiautomated analysis of left ventricular volume parameters from short-axis MR images. van der Geest RJ, et al. J. Comput. Assist. Tomogr. 1997 21 5 756 65 10.1097/00004728-199709000-00019 9294570 (Pubitemid 28049623)
21. Quantification in cardiac MRI. van der Geest RJ, Reiber JH, J. Magn. Reson. Imaging 1999 10 5 602 8 10.1002/(SICI)1522-2586(199911)10:5<602::AID- JMRI3>3.0.CO;2-C 10548768 (Pubitemid 29519761)
22. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Kim RJ, et al. Circulation 1999 100 19 1992 2002 10.1161/01.CIR.100.19.1992 10556226 (Pubitemid 29529292)
23. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. Kim RJ, et al. N. Engl. J. Med. 2000 343 20 1445 53 10.1056/NEJM200011163432003 11078769
24. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Cerqueira MD, et al. Int. J. Cardiovasc. Imaging 2002 18 1 539 42 12135124 (Pubitemid 34262671)
25. Low-gradient aortic valve stenosis myocardial fibrosis and its influence on function and outcome. Herrmann S, et al. J. Am. Coll. Cardiol. 2011 58 4 402 12 10.1016/j.jacc.2011.02.059 21757118
26. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. Dweck MR, et al. J. Am. Coll. Cardiol. 2011 58 12 1271 9 10.1016/j.jacc.2011.03.064 21903062
27. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. Ho CY, et al. N. Engl. J. Med. 2010 363 6 552 63 10.1056/NEJMoa1002659 20818890
28. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. O'Hanlon R, et al. J. Am. Coll. Cardiol. 2010 56 11 867 74 10.1016/j.jacc.2010.05.010 20688032
29. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Wu KC, et al. Circulation 1998 97 8 765 72 10.1161/01.CIR.97.8.765 9498540 (Pubitemid 28135339)
30. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. Bruder O, et al. J. Am. Coll. Cardiol. 2010 56 11 875 87 10.1016/j.jacc.2010.05. 007 20667520
31. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. Wu KC, et al. J. Am. Coll. Cardiol. 2008 51 25 2414 21 10.1016/j.jacc.2008.03.018 18565399 (Pubitemid 351826874)
32. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. Assomull RG, et al. J. Am. Coll. Cardiol. 2006 48 10 1977 85 10.1016/j.jacc.2006.07.049 17112987 (Pubitemid 44738448)
33. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. Azevedo CF, et al. J. Am. Coll. Cardiol. 2010 56 4 278 87 10.1016/j.jacc.2009.12.074 20633819
34. Detection of long-term progression of myocardial fibrosis in Duchenne muscular dystrophy in an affected family: a cardiovascular magnetic resonance study. Walcher T, et al. Eur. J. Radiol. 2011 80 1 115 9 10.1016/j.ejrad.2010. 07.005 20685051
35. Prevalence and distribution of regional scar in dysfunctional myocardial segments in Duchenne muscular dystrophy. Bilchick KC, et al. J. Cardiovasc. Magn. Reson. 2011 13 20 10.1186/1532-429X-13-20 21396105
36. Cardiac magnetic resonance assessment of dyssynchrony and myocardial scar predicts function class improvement following cardiac resynchronization therapy. Bilchick KC, et al. JACC Cardiovasc. Imaging 2008 1 5 561 8 10.1016/j.jcmg.2008.04.013 19356481
37. Increased activity of calcium leak channels in myotubes of Duchenne human and mdx mouse origin. Fong PY, et al. Science 1990 250 4981 673 6 10.1126/science.2173137 2173137
38. Oxidative stress and the pathogenesis of muscular dystrophies. Rando TA, Am. J. Phys. Med. Rehabil. 2002 81 11 Suppl 175 86 12409822
39. Genetic disruption of calcineurin improves skeletal muscle pathology and cardiac disease in a mouse model of limb-girdle muscular dystrophy. Parsons SA, et al. J. Biol. Chem. 2007 282 13 10068 78 10.1074/jbc.M609368200 17289669 (Pubitemid 47104644)
40. Myocardial inflammation in Duchenne muscular dystrophy as a precipitating factor for heart failure: a prospective study. Mavrogeni S, et al. BMC Neurol. 2010 10 33 10.1186/1471-2377-10-33 20492678
41. Myocarditis in a patient with Duchenne muscular dystrophy detected by cardiovascular magnetic resonance and cardiac biopsy. Mavrogeni S, Papavassiliou A, Cokkinos DV, Int. J. Cardiol. 2009 132 3 123 4 10.1016/j.ijcard.2007.10.015 18063150
42. Left ventricular T2 distribution in Duchenne muscular dystrophy. Wansapura JP, et al. J. Cardiovasc. Magn. Reson. 2010 12 1 14 10.1186/1532-429X-12-14 20298602
43. Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in duchenne muscular dystrophy mice. Rafael-Fortney JA, et al. Circulation 2011 124 5 582 8 10.1161/CIRCULATIONAHA.111.031716 21768542
44. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. Iles L, et al. J. Am. Coll. Cardiol. 2008 52 19 1574 80 10.1016/j.jacc.2008.06.049 19007595
45. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Jefferies JL, et al. Circulation 2005 112 18 2799 804 10.1161/CIRCULATIONAHA.104.528281 16246949 (Pubitemid 41641674)
46. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. Li JS, et al. J. Pediatr. 2010 157 2 282 7 10.1016/j.jpeds.2010.02.042 20400095
47. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. Rossignol P, et al. J. Am. Coll. Cardiol. 2011 58 19 1958 66 10.1016/j.jacc.2011.04.049 22032706